Delivery Order SPE2DB22D3004-SPE2DB25FQ73A
- Not listed
- The Defense Logistics Agency (DLA) awarded a $3,024.00 delivery order to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 200-62.5-25 60S, a combination inhalation powder medication used to treat chronic obstructive pulmonary disease. This firm fixed-price delivery order was awarded on August 11, 2025, with an ultimate completion date of August 12, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. The award was made through open competition with no...
- The Defense Logistics Agency awarded a $13,817.08 delivery order to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25 60S, a combination inhalation powder medication used in the treatment of chronic obstructive pulmonary disease. This competitively awarded, firm fixed price contract was issued on July 28, 2025, with an ultimate completion date of July 29, 2025. The place of performance is the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $8,409.03 to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25 60S, a combination inhalation powder medication used to treat chronic obstructive pulmonary disease. The competitively awarded, firm fixed-price delivery order was placed on August 8, 2025, with an ultimate completion date of August 11, 2025. Performance will be executed from AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a $22,946.07 delivery order to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 200-62.5-25, a combination inhaler medication used to treat chronic obstructive pulmonary disease. The contract was competitively awarded without set-aside provisions and carries a firm fixed price structure with an ultimate completion date of September 9, 2025. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,350.27 to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 200-62.5-25, a combination inhalation powder medication used to treat chronic obstructive pulmonary disease. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and is scheduled for completion by August 26, 2025. The award was processed on August 25, 2025, with performance taking place at AmerisourceBergen's corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $14,814.31 to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 60S, a combination inhalation powder medication used to treat chronic obstructive pulmonary disease. This firm fixed-price delivery order, issued on September 9, 2025, with an ultimate completion date of September 10, 2025, represents a non-competitive award under AmerisourceBergen's existing contract vehicle. The place of performance is located in...
- The Defense Logistics Agency awarded a delivery order valued at $1,847.34 to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25, a combination inhalation powder used in the treatment of chronic obstructive pulmonary disease. This firm fixed price delivery order, issued on August 5, 2025, represents a single transaction under a larger contract vehicle. The award was competitively awarded with no set-aside designation and is being performed at AmerisourceBergen's corporate office location...
- The Defense Logistics Agency awarded a Delivery Order valued at $16,547.64 to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 200-62.5-25, a combination inhalation powder used for chronic obstructive pulmonary disease management. The competitively awarded contract, which was not set aside for any specific business category, is firm fixed price and was executed on September 11, 2025, with an ultimate completion date of September 12, 2025. The product will be performed and delivered from...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $69,848.93 to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 200-62.5-25, a combination inhalation powder medication used primarily for chronic obstructive pulmonary disease (COPD) management. The order, which was competitively awarded without a set-aside designation, specifies delivery of 60 doses with an ultimate completion date of September 18, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,713.88 to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25, a combination inhalation powder medication used to treat chronic obstructive pulmonary disease. The contract, awarded on July 14, 2025, with an ultimate completion date of July 15, 2025, was issued under a firm fixed-price delivery order mechanism with no set-aside designation. This award represents a competitive procurement that leverages...
- SPE2DB22D3004Indefinite Delivery Contract
- SPE2DB22D3004-SPE2DB25FQ73ADelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,733.86 to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 100-62.5-25, a combination inhalation powder medication used in the treatment of chronic obstructive pulmonary disease (COPD). This firm fixed price delivery order, awarded on September 15, 2025, represents a competitive procurement with no set-aside designation and is scheduled for completion by September 16, 2025. The product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate headquarters. This delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a prime vendor under this comprehensive global pharmaceutical support vehicle, AmerisourceBergen supplies a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including support to the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. The company's selection demonstrates its capability to meet federal medical procurement requirements through open competition and reflects its established role as a critical supplier within the DLA's medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.7k | 9/15/25 |